Nephrotoxicity of hydroxyethyl starch 130/0.4 infusion in patients receiving coronary artery bypass surgery: a retrospective study
نویسندگان
چکیده
Background: Hydroxyethyl starch (HES) is helpful to maintain the stable haemodynamics in patients receiving cardiac surgery. However, there are concerns regarding the nephrotoxicity of HES. Objectives: This study was to evaluate the nephrotoxicity of HES 130/0.4 in patients receiving on-pump coronary artery bypass surgery. Methods: Patients receiving on-pump coronary artery bypass surgery in Xinqiao Hospital between September 1, 2012 and December 31, 2014 were retrospectively reviewed. Acute kidney injury (AKI) was defined according to the RIFLE criteria, and the renal injury (sCystatin C) was compared between patients with and without HES 130/0.4 infusion in the first 72 h after surgery. Results: A total of 149 patients were included. The incidence of AKI within 72 h was similar between two groups, and the risk for AKI (95% CI, 0.979-1.139) was not increased by hetastarch, even at a dose of 37 ml/kg. Conclusion: HES 130/0.4 does not increase the risk for AKI when it is used for the volume therapy in patients receiving coronary artery bypass surgery, and may neither enhance tubular injury nor alter the glomerular filtration.
منابع مشابه
Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses.
BACKGROUND Hydroxyethyl starch (HES) 130/0.4 may impair blood coagulation less than other HES solutions and, thus, may be used at larger doses without increasing the risk of postoperative bleeding. This study tested the hypothesis that volume replacement with 6% HES 130/0.4 at a dose of up to 50 ml/kg does not increase blood loss and transfusion requirements in elective coronary artery bypass s...
متن کاملHydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study
BACKGROUND Since the advent of cardiopulmonary bypass, many efforts have been made to avoid the complications related with it. Any component of the pump participates in occurrence of these adverse events, one of which is the type of prime solution. In this study, we aimed to compare the effects of 6% hydroxyethyl starch 130/0.4 with a commonly used balanced electrolyte solution on postoperative...
متن کاملComparison of 4% Succinylated Gelatin with 6% Hydroxyethyl Starch 130/0.4 for Preloading Prior to Cardiopulmonary Bypass in Coronary Artery Bypass Grafting Patients
Aims and Objective: The present study was carried out with an objective to compare 4% succinylated gelatin with 6% hydroxyethyl starch 130/0.4 for preloading prior to cardiopulmonary bypass in coronary artery bypass grafting patients with respect to haemodynamics status, blood loss, transfusion requirement, ICU stay and complication. Methods: The study enrolling 60 patients of either sex, aged ...
متن کاملEffects of 6% hydroxyethyl starch 130/0.4 on postoperative blood loss and kidney injury in off-pump coronary arterial bypass grafting
We retrospectively evaluated the effects of 6% hydroxyethyl starch (HES) 130/0.4 on postoperative blood loss and acute kidney injury (AKI) in patients undergoing off-pump coronary artery bypass grafting (OPCAB).Electronic medical records of 771 patients who underwent OPCAB in our hospital between July 2012 and July 2014 were reviewed, and 249 patients without intraoperative HES-exposure (group ...
متن کاملAcute kidney injury in cardiac surgery patients receiving hydroxyethyl starch solutions
In a retrospective study by a Canadian team [1], pentastarch infusion was a dose-related independent risk factor for acute kidney injury (AKI) after cardiac surgery. In a new retrospective cardiac surgery study by that team [2], 83% of patients received hydroxyethyl starch (HES) 130/ 0.4. For unexplained reasons, 25 to 43% of patients received both HES 130/0.4 and pentastarch. The team 'hypothe...
متن کامل